.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,622,828

« Back to Dashboard

Details for Patent: 5,622,828

Title: High-affinity oligonucleotide ligands to secretory phospholipase A2 (sPLA.sub.2)
Abstract:This invention discloses high-affinity oligonucleotide ligands to human secretory phospholipase A2 (sPLA.sub.2), specifically RNA ligands having the ability to bind to sPLA.sub.2, and the methods for obtaining such ligands.
Inventor(s): Parma; David H. (Boulder, CO), Gold; Larry (Boulder, CO)
Assignee: Nexstar Pharmaceuticals, Inc. (Boulder, CO)
Filing Date:Mar 06, 1995
Application Number:08/399,412
Claims:1. A method for identifying nucleic acid ligands and nucleic acid ligand sequences to secretory phospholipase A2 (sPLA.sub.2) comprising:

a) contacting a candidate mixture of nucleic acids with sPLA.sub.2, wherein nucleic acids having an increased affinity to the sPLA.sub.2 relative to the candidate mixture may be partitioned from the remainder of the candidate mixture;

b) partitioning the increased affinity nucleic acids from the remainder of the candidate mixture; and

c) amplifying the increased affinity nucleic acids to yield a mixture of nucleic acids enriched for nucleic acid sequences with relatively higher affinity and specificity for binding to sPLA.sub.2, whereby nucleic acid ligands and nucleic acid ligand sequences of sPLA.sub.2 may be identified.

2. The method of claim 1 further comprising:

d) repeating steps a), b) and c).

3. The method of claim 1 wherein said candidate mixture is comprised of single-stranded nucleic acids.

4. The method of claim 3 wherein said single-stranded nucleic acids are ribonucleic acids.

5. The method of claim 3 wherein said single-stranded nucleic acids are deoxyribonucleic acids.

6. A nucleic acid ligand to sPLA.sub.2 identified according to the method of claim 1.

7. A purified and isolated non-naturally occurring nucleic acid ligand to secretory phospholipase A.sub.2 (sPLA.sub.2).

8. The nucleic acid ligand of claim 7 which is a ribonucleic acid ligand.

9. The RNA ligand of claim 8 wherein said RNA ligand is selected from the group consisting of the nucleotide sequences set forth in Table II, SEQ ID NOS:10-122.

10. A purified and isolated non-naturally occuring RNA ligand to sPLA.sub.2 comprising the sequences selected from the group consisting of SEQ ID NOS: 97-100.

11. The ligand of claim 7 wherein said ligand comprises a chemically modified pyrimidine base selected from the group consisting of 2'- NH.sub.2 pyrimidines and 2'-F pyrimidines.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc